Government-Owned Inventions; Availability for Licensing, 38147 [2020-13656]

Download as PDF Federal Register / Vol. 85, No. 123 / Thursday, June 25, 2020 / Notices Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cellular and Molecular Immunology. Date: July 23, 2020. Time: 1:00 p.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Deborah Hodge, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4207, MSC 7812, Bethesda, MD 20892, (301) 435– 1238, hodged@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Cell/Molecular Biology and Instrumentation/Systems Development. Date: July 24, 2020. Time: 10:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm 6188, MSC 7804, Bethesda, MD 20892, (301) 435–1267, belangerm@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cancer Prevention. Date: July 24, 2020. Time: 10:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Jeffrey Smiley, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6194, MSC 7804, Bethesda, MD 20892, 301–594– 7945, smileyja@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: June 19, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–13696 Filed 6–24–20; 8:45 am] BILLING CODE 4140–01–P jbell on DSKJLSW7X2PROD with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. VerDate Sep<11>2014 19:15 Jun 24, 2020 Jkt 250001 ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing Michael Shmilovich, shmilovm@nih.gov, the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows. SUMMARY: Liposome Nanodecoys That Protect Against SARS–COV–2 Available for licensing and commercial development are patent rights covering a liposomal vesicle (a ‘‘nanodecoy’’) with a lipid bilayer with one or more proteins recognized by a pathogen (e.g., SARS–CoV–2) and one or more cytokine receptors (such as IL– 6; receptors: CD126, CD130; IL–1; receptors: CD121a, CD121b, IL–8; receptors: IL–8RB; IL–12; receptors: CD212; TNF–a; receptors: CD120a, CD120b; IFN-g; receptors: CD119, IFN– a/b; receptors: CD118) and wherein the liposomal vesicle is non-replicating. Nanodecoys that display angiotensinconverting enzyme 2 (ACE2) and multiple cytokine receptors, are able to sequester SARS–CoV–2 and inhibit viral replication and infection, as well as to mitigate COVID–19–induced cytokine release syndrome (CRS) in susceptible cells. Potential Commercial Applications: • COVID–19 • SARS–CoV–2 • Cytokine release syndrome Æ immunosuppression • Viral inhibition Æ Receptor binding competition Development Stage: • Preclinical Inventors: Xiaoyuan (Shawn) Chen (NIBIB) and Lang Rao (NIBIB). Intellectual Property: HHS Reference No. E–144–2020–0–US–01 ‘‘Engineered Cell Membrane Nanodecoys To Protect Against COVID–19;’’ U.S. Provisional Patent Application 63/038,380 filed June 12, 2020. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 38147 Dated: June 17, 2020. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2020–13656 Filed 6–24–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Environmental Health Sciences; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel; Bioremediation Superfund. Date: July 16, 2020. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Environmental Health Sciences, Keystone Building, 530 Davis Drive, Durham, NC 27709 (Virtual Meeting). Contact Person: Laura A. Thomas, Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, (919) 541–2824, laura.thomas@ nih.gov. Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel; Training in Environmental Health Sciences. Date: July 17, 2020. Time: 11:30 a.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Environmental Health Sciences, Keystone Building, 530 Davis Drive, Durham, NC 27709 (Virtual Meeting). Contact Person: Linda K. Bass, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, National Institute of Environmental Health Sciences, P.O. Box 12233, MD EC–30, Research Triangle Park, NC 27709, (984) 287– 3236, bass@niehs.nih.gov. E:\FR\FM\25JNN1.SGM 25JNN1

Agencies

[Federal Register Volume 85, Number 123 (Thursday, June 25, 2020)]
[Notices]
[Page 38147]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-13656]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing Michael Shmilovich, [email protected], the indicated 
licensing contact at the National Heart, Lung, and Blood, Office of 
Technology Transfer and Development Office of Technology Transfer, 31 
Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 
301-402-5579. A signed Confidential Disclosure Agreement may be 
required to receive any unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Liposome Nanodecoys That Protect Against SARS-COV-2

    Available for licensing and commercial development are patent 
rights covering a liposomal vesicle (a ``nanodecoy'') with a lipid 
bilayer with one or more proteins recognized by a pathogen (e.g., SARS-
CoV-2) and one or more cytokine receptors (such as IL-6; receptors: 
CD126, CD130; IL-1; receptors: CD121a, CD121b, IL-8; receptors: IL-8RB; 
IL-12; receptors: CD212; TNF-[alpha]; receptors: CD120a, CD120b; IFN-
[gamma]; receptors: CD119, IFN-[alpha]/[beta]; receptors: CD118) and 
wherein the liposomal vesicle is non-replicating. Nanodecoys that 
display angiotensin-converting enzyme 2 (ACE2) and multiple cytokine 
receptors, are able to sequester SARS-CoV-2 and inhibit viral 
replication and infection, as well as to mitigate COVID-19-induced 
cytokine release syndrome (CRS) in susceptible cells.
    Potential Commercial Applications:

 COVID-19
 SARS-CoV-2
 Cytokine release syndrome
    [cir] immunosuppression
 Viral inhibition
    [cir] Receptor binding competition

    Development Stage:

 Preclinical

    Inventors: Xiaoyuan (Shawn) Chen (NIBIB) and Lang Rao (NIBIB).
    Intellectual Property: HHS Reference No. E-144-2020-0-US-01 
``Engineered Cell Membrane Nanodecoys To Protect Against COVID-19;'' 
U.S. Provisional Patent Application 63/038,380 filed June 12, 2020.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: June 17, 2020.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2020-13656 Filed 6-24-20; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.